What Kardiket Retard Treats: Main Uses and Benefits

Kardiket Retard is commonly used to help with the management of conditions presenting with symptoms related to physical discomfort and systemic imbalance, helping to ease the overall symptom burden. It is primarily applied across domains where additional symptomatic support is needed for managing episodic chest discomfort and providing supportive relief in conditions marked by heightened systemic burden.

---

Managing Episodic Chest Discomfort

The medicine is used for managing episodic chest discomfort, a symptom often associated with temporary physiological imbalance. It is relevant in clinical settings marked by heightened patient distress, particularly for easing symptoms that interfere with daily functioning, especially those associated with episodic chest discomfort and conditions involving physiological strain.

The medication is applied in situations involving symptomatic discomfort. This supportive management helps address symptom clusters that may appear suddenly or intensify over time, providing supportive relief that helps patients cope more steadily with difficult episodes.

Quick Fact: Support for Episodic Chest Discomfort Kardiket Retard helps maintain a sense of stability when circulatory symptoms become more noticeable, contributing to improved comfort during symptomatic phases.

Regulatory References

1. is used in situations involving symptomatic discomfort

Official Eligibility and Contraindications

The eligibility profile for Kardiket Retard (Isosorbide Dinitrate) is strictly defined by regulatory authorities to ensure appropriate use. Most adults aged 18 years and over are permitted to use the medicine under standard labeled conditions.

Absolute Prohibitions (Contraindications): The medicine is strictly contraindicated in the following populations:

• Patients with known hypersensitivity to isosorbide dinitrate or any other organic nitrates.
• Patients concurrently taking Phosphodiesterase 5 (PDE-5) inhibitors (e.g., sildenafil) or the soluble guanylate cyclase stimulator riociguat.
• Patients with severe hypotension (very low blood pressure), circulatory collapse, or marked anaemia.
• Patients with specific cardiac conditions, including Hypertrophic Obstructive Cardiomyopathy (HOCM).

Restricted and Age-Specific Use:

• Pediatric Use: The medicine is not recommended for children and adolescents under 18 years old as its safety and effectiveness have not been established by regulatory bodies.
• Conditional Use: Use requires caution in older adults and patients with severe hepatic or renal impairment.
• Pregnancy/Lactation: Use is not recommended unless determined to be essential by a physician, as safety is unestablished.

Interactions with other medicines and products

This section summarizes the official interaction patterns for Kardiket Retard (Isosorbide Dinitrate) as documented in government regulatory labeling.

---

Contraindicated Combinations

Co-administration with specific drug classes is formally prohibited due to the risk of severe pharmacodynamic interaction resulting in profound hypotension:

• Phosphodiesterase-5 (PDE5) Inhibitors: This includes Sildenafil, Tadalafil, Vardenafil, and Avanafil. This combination is strictly contraindicated due to the potential for a severe and life-threatening drop in blood pressure.
• Riociguat: The soluble guanylate cyclase stimulator Riociguat is also contraindicated for use with nitrates.

---

Pharmacodynamic and Substance Interactions

Interactions that potentiate the hypotensive effect are documented with:

• Antihypertensive Agents: Concurrent use with other blood pressure lowering medicines, such as beta-blockers, ACE inhibitors, calcium antagonists, and diuretics, may result in an additive hypotensive effect.
• Alcohol: Consumption of alcohol may enhance the vasodilating and hypotensive actions of Isosorbide Dinitrate.
• Saproterin (BH4): Caution is recommended with co-administration as this substance affects nitric oxide metabolism.

---

Exposure-Modifying and Timing Rules

Nitrates may increase the blood level and bioavailability of Dihydroergotamine, which can enhance its hypertensive effect. Due to the severe nature of contraindicated interactions, specific timing separation rules are mandated for certain PDE5 inhibitors: administration of nitrates is restricted to at least 48 hours after the last Tadalafil dose and 24 hours after Sildenafil or Vardenafil.

Mechanism 1: Activating the Nitric Oxide ( NO) Signaling Cascade

Kardiket Retard acts as a prodrug that is enzymatically converted within the body to release the gaseous signaling molecule, Nitric Oxide ( NO). This NO activates the enzyme Soluble Guanylyl Cyclase ( sGC) inside the vascular smooth muscle cells, which initiates the second messenger pathway that mediates smooth muscle relaxation.

---

Mechanism 2: cGMP-Mediated Vascular Smooth Muscle Relaxation

The activation of sGC leads to high concentrations of the cellular messenger cyclic GMP ( cGMP), which is the immediate cause of the drug's vasodilatory effect. This increase in cGMP leads to the deactivation of the contractile process and causes vascular smooth muscle relaxation (vasodilation).

---

Mechanism 3: Reducing Cardiac Preload to Lower Oxygen Demand

The resulting vasodilation, which preferentially affects venous capacitance vessels, increases peripheral venous pooling. This action lowers the volume of blood returning to the heart (Preload), which is the primary physiological consequence that directly lowers myocardial oxygen demand ( MVO2).

Kardiket Retard is an oral medication supplied as a modified-release capsule or tablet formulation intended for long-term prophylactic use. This specific form necessitates that the unit must be swallowed whole with a sufficient amount of fluid and must not be chewed, crushed, or split, as doing so would compromise the controlled-release mechanism and prescribed administration requirements. The medicine can generally be taken independently of meals.

Official Dosing and Schedule

The standard adult regimen typically begins with an oral dose of 20 mg once daily. Based on the patient's requirements and established protocols, the dose may be subsequently adjusted to a maintenance regimen, often up to 40 mg once daily. Regardless of the final dose, the administration schedule is cyclical and a procedural requirement is that it must include a mandated nitrate-free interval—usually 10 to 12 hours—within every 24-hour period to adhere to the administration protocol.

Dosing instructions for the paediatric population are not defined for this formulation, and use in children is generally not advised. For cases involving a forgotten dose, if the time for the next scheduled dose is near, the protocol indicates that the missed dose should be skipped; a double dose must never be taken to compensate for the omission. These procedural constraints define the standardized administration protocol.

Research Evidence / Overview of Studies

This section summarizes research evidence on studies that evaluated the drug’s performance measures and potential effects in various patient groups. The active ingredient, isosorbide dinitrate (ISDN), is a long-acting organic nitrate used in the management of angina pectoris (chest pain) and certain types of heart failure.

---

Efficacy Data from Clinical Trials

Clinical trials have investigated the effect of the sustained-release (Retard) formulation of isosorbide dinitrate on symptoms of chronic stable angina. Research tracked whether participants experienced improvements in measures such as exercise tolerance and the frequency of anginal attacks.

• Exercise Tolerance: Studies involving patients with stable angina found that administration of the sustained-release form was associated with a statistically significant increase in total exercise time compared to placebo. This suggests that the drug may prolong the time until angina symptoms or signs of myocardial ischemia appear during physical exertion.
• Anti-Ischemic Effect: Trials have evaluated the effect of different dosing regimens to prevent the loss of effectiveness (nitrate tolerance). Results support the concept that a dosing schedule incorporating a low-nitrate or nitrate-free interval is essential for maintaining anti-ischemic activity during long-term use.

---

Use in Specific Patient Populations

Comparative Studies and Dosing

Studies comparing a single high dose of the sustained-release formulation (e.g., 120 mg once daily) against divided doses of lower-strength sustained-release formulations (e.g., 40 mg three times daily) found that the once-daily, higher-dose regimen was associated with greater anti-anginal efficiency and better patient tolerance.

Renal and Hepatic Impairment

For the active substance isosorbide dinitrate, studies and clinical data generally indicate that dose adjustment is not typically required for patients with most degrees of renal or hepatic impairment. However, use in patients with advanced liver or kidney disease should be discussed with a specialist.

Key Studies & References

1. Isosorbide Dinitrate: Drug Monograph and FDA Labeling

Common questions about Kardiket Retard (FAQ)

Q: Is Kardiket Retard used to treat a sudden, ongoing angina attack?

A: Official drug information states that this medication is intended for the prevention of chest pain. Because Kardiket Retard is a modified-release formulation designed for prolonged action, it is not described as being for the treatment of chest pain that is currently happening (acute episodes).

---

Q: What is the difference between Kardiket Retard (isosorbide dinitrate) and nitroglycerin?

A: Both are classified as nitrates used for heart conditions. According to authoritative sources, the key difference is their action time: Kardiket Retard is a long-acting nitrate used for prevention, while nitroglycerin is typically a short-acting preparation used for the immediate relief of existing symptoms.

---

Q: How long does the headache side effect from Kardiket Retard usually last?

A: The headache side effect is commonly observed when a person first starts taking the medicine. Official safety information indicates that this effect is commonly observed at the start of therapy and may diminish or gradually become less severe with continued use.

---

Q: What happens if a patient suddenly stops taking Kardiket Retard?

A: Research examined in medical literature suggests a possibility that abrupt cessation of continuous nitrate treatment may lead to a rebound increase in myocardial ischaemia (worsening heart-related symptoms).

---

Q: Are there studies on the use of Kardiket Retard in children?

A: Official regulatory bodies state that the safety and effectiveness of this medicine have not yet been established in children and adolescents. Due to this lack of established data, the medicine is generally listed as being not recommended for use in the pediatric population.

---

Q: Does Kardiket Retard affect a person's ability to drive or operate machinery?

A: Official warnings state that, because this medicine can cause dizziness or affect coordination, it can impact a person's alertness. Activities such as driving or operating machinery should be avoided until an individual knows how the drug affects their coordination and alertness.

---

Q: Does the effectiveness of Kardiket Retard change over a long period of use?

A: Studies and official information indicate that a loss of effectiveness, known as nitrate tolerance, may occur during long-term use. This is why the dosing schedule requires a mandatory nitrate-free interval to help maintain the drug's anti-ischemic activity.

---

Q: What should be done if the angina symptoms seem to be getting worse while on the medication?

A: Official warnings state that a healthcare provider should be contacted immediately if a person notices their angina pain is getting worse or more frequent. This is because worsening symptoms may require timely medical assessment.

---

Q: Can Kardiket Retard be prescribed for conditions other than angina, such as heart failure?

A: Yes. Official drug information confirms that the medicine is also taken alongside other medications to treat certain conditions associated with heart failure.

---

Q: Why is Kardiket Retard considered a "long-acting" medicine?

A: The medicine is classified as a long-acting nitrate because it is specifically formulated as a modified-release or sustained-release tablet/capsule. This design ensures the active ingredient is released slowly and consistently over many hours, providing a prolonged therapeutic effect for prevention.

---

Q: Is there a risk of Methemoglobinemia with Kardiket Retard?

A: Official labeling states that nitrate ions released during the medicine's metabolism can cause an increase in methemoglobin in the blood. Case reports of this serious condition have been noted in association with organic nitrates.

---

Q: Does Kardiket Retard interact with any common over-the-counter cold or pain relief medicines?

A: Official guidance states that Paracetamol is safe to take with it. However, official guidance cautions against the regular use of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen or aspirin without a physician's awareness, as there is a potential for them to worsen certain heart conditions.

---

Q: Does Kardiket Retard interact with any vitamins or herbal supplements?

A: Regulatory resources advise that there is not enough scientific information to definitively confirm the safety of all complementary medicines, herbal remedies, and supplements. This is because most supplements are not tested for interactions with prescription drugs.

---

Q: Are there any food or beverage restrictions when using Kardiket Retard?

A: Official product information, such as the Canadian Product Monograph, indicates that interactions with food have not been established. This suggests no known formal restrictions regarding specific food or non-alcoholic beverage types.

---

Q: Does Kardiket Retard affect people with kidney problems differently?

A: Official medical considerations indicate that patients with renal dysfunction (kidney impairment) are at an increased risk of hypotension (low blood pressure). Official considerations indicate that close monitoring and a reduced dose may be necessary when this medicine is used by patients with renal dysfunction.

---

Q: Is it true that taking Kardiket Retard can cause flushing or warmth?

A: Yes. According to official documentation, side effect lists include flushing as a common side effect. Flushing is often described as a feeling of warmth, redness, or a tingly sensation.

---

Q: Can a patient continue to exercise or play sports while taking this medicine?

A: Official warnings note that dizziness, lightheadedness, or fainting is more likely to occur when a person is exercising or is standing for long periods. Official warnings state that patients should use extra care during any physical exertion.

---

Q: Does this medicine have any impact on a patient's sex life other than the ED drug interaction?

A: Official drug information lists the inability to have or keep an erection as a documented side effect of this medicine. This is a potential effect separate from the severe interaction with erectile dysfunction (ED) drugs.

---

Q: Are there specific food types that affect the absorption of the slow-release tablet?

A: Official product information does not indicate specific food types that affect the absorption. The product monograph states that interactions with food have not been established.

---

How to Store and Dispose of Kardiket Retard

Storage of Kardiket Retard (Isosorbide Dinitrate) must strictly follow official regulatory requirements to ensure product stability and safety.

Mandatory Storage and Protection

The medicine must be stored at a temperature not exceeding 25°C (seventy-seven degrees Fahrenheit). It is essential to keep the product protected from light and stored within its original container.

For child safety, the medicine must always be stored out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Kardiket Retard must be disposed of in accordance with local requirements for pharmaceutical waste. The official labeling strictly prohibits discarding the medicine via wastewater (flushing down the toilet or sink) or household waste. Unused product should be returned to a pharmacy or official collection point for proper environmental handling.